With the development of newer weight loss agents with more marked effects on body weight,
in some instances approaching the weight-loss effects of bariatric surgery, we may soon …

The recently reported SELECT trial (Semaglutide Effects on Heart Disease and Stroke in
Patients With Overweight or Obesity) 3 tested this hypothesis using the higher-dose …

More than half the world population is expected to be overweight or obese by the year 2035
[1]. Obesity and atherosclerotic cardiovascular disease have always been a fatal …

Obesity is a chronic condition associated with a range of comorbidities, physical inactivity,
and decreased quality of life. Disturbingly, the prevalence continues to escalate, children …

Obesity is a global epidemic associated with over 200 health complications and a significant
risk of developing cardiovascular disease (CVD), partly by increasing classical risk factors …

Overweight or obesity has been independently associated with increased cardiovascular
risk, yet interventional trials of lifestyle or pharmacologic management strategies for …

• In the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or
Obesity trial, the SELECT Investigators tested the hypothesis that the addition of …

Progress in the field of obesity may seem to have progressed at a snail's pace, but
tremendous advances have been made during the last few decades in our understanding of …

Treatment with the glucagon-like peptide 1 receptor agonist semaglutide, administered
subcutaneously at a dose of 2.4 mg once per week, reduces the risk of major cardiovascular …

Obesity is a major risk factor for cardiovascular disease, yet management remains poor.
Cardiologists and healthcare professionals treating people with high cardiovascular risk are …